AnaptysBio (NASDAQ:ANAB) Shares Up 5.2%

AnaptysBio, Inc. (NASDAQ:ANABGet Free Report)’s share price traded up 5.2% on Friday . The stock traded as high as $24.46 and last traded at $24.09. 105,079 shares changed hands during mid-day trading, a decline of 68% from the average session volume of 326,402 shares. The stock had previously closed at $22.89.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. JPMorgan Chase & Co. dropped their price objective on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, April 1st. Wells Fargo & Company assumed coverage on shares of AnaptysBio in a research report on Thursday, April 11th. They issued an “overweight” rating and a $56.00 target price for the company. Wedbush restated an “outperform” rating and issued a $34.00 target price on shares of AnaptysBio in a research report on Friday, May 10th. BTIG Research assumed coverage on shares of AnaptysBio in a research report on Monday, February 26th. They issued a “buy” rating and a $55.00 target price for the company. Finally, Leerink Partnrs restated an “outperform” rating on shares of AnaptysBio in a research report on Tuesday, April 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $46.38.

View Our Latest Research Report on ANAB

AnaptysBio Stock Performance

The company has a market capitalization of $663.85 million, a P/E ratio of -3.92 and a beta of -0.33. The firm’s fifty day moving average is $23.47 and its 200-day moving average is $22.79.

AnaptysBio (NASDAQ:ANABGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.10). The company had revenue of $7.18 million for the quarter, compared to the consensus estimate of $4.55 million. AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. As a group, analysts expect that AnaptysBio, Inc. will post -6.04 EPS for the current fiscal year.

Insiders Place Their Bets

In other AnaptysBio news, Director Hollings Renton sold 1,950 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $23.16, for a total transaction of $45,162.00. Following the sale, the director now directly owns 1,950 shares of the company’s stock, valued at approximately $45,162. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Hollings Renton sold 1,950 shares of the business’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $23.16, for a total value of $45,162.00. Following the transaction, the director now owns 1,950 shares in the company, valued at approximately $45,162. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dennis Mulroy sold 1,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $23.72, for a total transaction of $35,580.00. Following the completion of the transaction, the chief financial officer now owns 964 shares in the company, valued at approximately $22,866.08. The disclosure for this sale can be found here. Insiders have sold 6,450 shares of company stock valued at $145,002 in the last ninety days. 33.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Algert Global LLC lifted its position in shares of AnaptysBio by 40.2% during the 3rd quarter. Algert Global LLC now owns 16,530 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 4,740 shares during the period. Caxton Associates LP acquired a new position in AnaptysBio during the third quarter worth $268,000. Eventide Asset Management LLC acquired a new position in AnaptysBio during the third quarter worth $7,669,000. Jacobs Levy Equity Management Inc. raised its holdings in AnaptysBio by 4.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 206,785 shares of the biotechnology company’s stock worth $3,714,000 after buying an additional 8,064 shares during the last quarter. Finally, Hudson Bay Capital Management LP raised its holdings in AnaptysBio by 100.0% during the third quarter. Hudson Bay Capital Management LP now owns 100,000 shares of the biotechnology company’s stock worth $1,796,000 after buying an additional 50,000 shares during the last quarter.

AnaptysBio Company Profile

(Get Free Report)

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

Recommended Stories

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.